



- (51) International Patent Classification:
A61K 31/711 (2006.01) *C12N 15/85* (2006.01)
A61P 9/00 (2006.01)
- (21) International Application Number:
PCT/US2014/029921
- (22) International Filing Date:
15 March 2014 (15.03.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/792,954 15 March 2013 (15.03.2013) US
- (71) Applicants: **THE CLEVELAND CLINIC FOUNDATION** [US/US]; 9500 Euclid Avenue, Cleveland, OH 44195 (US). **JUVENTAS THERAPEUTICS, INC.** [US/US]; 3615 Superior Avenue, Suite 4403C, Cleveland, OH 44114 (US).
- (72) Inventor; and
(71) Applicant : **FISHER, Scott, J.**; 32571 Trailwood Court, Solon, OH 44139 (US).
- (72) Inventors: **PENN, Marc, S.**; 26091 Shaker Boulevard, Beachwood, OH 44122 (US). **ARAS, Rahul**; 150 Hartford Court, Broadview Heights, OH 44147 (US). **PASTORE, Joseph**; 7004 Easton Way W, Mentor, OH 44060 (US). **MILLER, Timothy, J.**; 2240 Delaware Drive, Cleveland Heights, OH 44106 (US).
- (74) Agents: **VALLA, S. Maurice** et al.; Baker & Hostetler LLP, 2929 Arch Street, Cira Centre, 12th Floor, Philadelphia, PA 19104-2891 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: RETROGRADE DELIVERY OF SDF-1 FOR TREATMENT OF MYOCARDIAL INFARCTION

(57) Abstract: Described herein are methods of treating a subject with a cardiomyopathy by administering to the subject's heart, via percutaneous retrograde coronary sinus perfusion, a pharmaceutical composition that comprises a DNA plasmid encoding SDF-1 and a pharmaceutically acceptable carrier or diluent.




Figure 4



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

6 November 2014

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/29921

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/711, A61P 9/00, C12N 15/85 (2014.01)

USPC - 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 31/711; A61P 9/00; C12N 15/85

USPC: 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); Google/Google Scholar; NCBI/PubMed; ProQuest; 'SDF-1,' patient, cardiomyopathy, plasmid, 'pharmaceutical carrier,' administer, heart, coronary, 'myocardial infarction,' 'ACL-01110,' 'JVS-100'

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 2012/0289586 A1 (PENN, MS et al.); November 15, 2012; paragraphs [0006], [0057], [0109], [0119], [0173]; figure 7; Claim 2; SEQ ID NO: 4	1, 3/1, 4/1, 17 — 2, 3/2, 4/2, 18
Y	MURPHY, E et al. Coding Potential Of Laboratory And Clinical Strains Of Human Cytomegalovirus. Proc Natl Acad Sci USA. 09 December 2003; Vol. 100, No. 25; pages 14976-81; Epub 01 December 2003; GenBank: AC146999.1.	2, 3/2, 4/2, 18
Y	FAN, J et al. APOBEC3G Generates Nonsense Mutations In Human T-Cell Leukemia Virus Type 1 Proviral Genomes In Vivo. J Virol. July 2010; Vol. 84, No. 14; pages 7278-87. DOI: 10.1128/JVI.02239-09; Epub 12 May 2010; GenBank: AB513134.1.	2, 3/2, 4/2, 18
Y	DU, Y et al. Highly Efficient Expression Of Interleukin-2 Under The Control Of Rabbit Beta-Globin Intron II Gene Enhances Protective Immune Responses Of Porcine Reproductive And Respiratory Syndrome (PRRS) DNA Vaccine In Pigs. PLoS One. 06 March 2014, Vol. ;9, No. 3; page e90326. DOI: 10.1371/journal.pone.0090326. eCollection 2014; GenBank: KF703899.1.	2, 3/2, 4/2, 18

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 August 2014 (05.08.2014)

Date of mailing of the international search report

29 AUG 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/29921

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 5-16
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.